Tech Transfer: Lilly, Purdue University Work To Optimize Injectable Therapies

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Five-year collaboration between the Indiana-based pharma and university also hopes to develop predictive modeling for clinical development success.

Tech Transfer regular column feature image

A longstanding series of small collaborations between geographically adjacent partners – Eli Lilly & Co. and Purdue University – now is resulting in a five-year, $52m technical collaboration in which the pharma and university will try to tackle ways to optimize injectable therapies and develop modeling that can improve the success rate in clinical development.

Announced July 6, the agreement between Indianapolis-headquartered Lilly and Purdue is noteworthy for several reasons, not least of which is...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.